Express Pharma
JULY 27, 2024
India’s pharmaceutical industry has emerged as a global powerhouse, earning the moniker ‘pharmacy of the world’. This remarkable journey is underpinned by a complex interplay of factors, including robust R&D, skilled manpower, and a conducive regulatory environment. However, the industry now stands at a critical juncture, grappling with the intricate issue of Intellectual Property Rights (IPR) protection.
Drug Patent Watch
JULY 27, 2024
This chart shows the pharmaceutical companies with the most patents in South Africa. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaTech
JULY 27, 2024
Scorpius Holdings is set to launch its first CGMP manufacturing campaign at its San Antonio, Texas, facility for mammalian cell culture in the 2024 third quarter.
Drug Patent Watch
JULY 27, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Pharmacy Times
JULY 27, 2024
One of the most important drivers of a patients’ uncontrolled hypertension is medication nonadherence.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
JULY 27, 2024
Annual Drug Patent Expirations for RETEVMO Retevmo is a drug marketed by Loxo Oncol Eli Lilly and is included in two NDAs. It is available from one supplier.
Drug Patent Watch
JULY 27, 2024
ALOXI (palonosetron hydrochloride) Helsinn hlthcare Patent: 7,947,725 Expiration: Jul 30, 2024 See More … For more information on how DrugPatentWatch […] Source
Expert insights. Personalized for you.
102 
Let's personalize your content